PRISM ALS has launched an initiative to develop patient-derived induced pluripotent stem cell (iPSC) models that represent both genetic and sporadic forms of amyotrophic lateral sclerosis. The program aims to create a diverse panel of well-characterized stem cell models that researchers can access for ALS studies.
The initiative focuses on capturing the biological complexity of ALS by developing iPSC models from actual patients rather than relying solely on laboratory-created cell lines. These patient-derived models are intended to better represent the diversity of ALS presentations, including both inherited genetic forms and sporadic cases that arise without clear genetic causes.